Skip to main content

and
  1. No Access

    Article

    The Long-Term Cost Effectiveness of Treatments for Benign Prostatic Hyperplasia

    Excellent treatment outcomes with long-term durability and few adverse effects are expectations of treatments for chronic conditions. The long-term cost effectiveness of newer treatments for benign prostatic h...

    Rachael L. DiSantostefano, Andrea K. Biddle, John P. Lavelle in PharmacoEconomics (2006)

  2. No Access

    Article

    The effect of cost construction based on either DRG or ICD-9 codes or risk group stratification on the resulting cost-effectiveness ratios

    Background: As cost-effectiveness analyses (CEAs) are increasingly used to inform policy decisions, there is a need for more information on how different cost determination methods affect cost es...

    Dr Elinor C. G. Chumney, Andrea K. Biddle, Kit N. Simpson in PharmacoEconomics (2004)